Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cognitive tests and assessment

Topic: Brain proteins, microglia and lab models

Alzheimer's disease (AD) is a chronic neurodegenerative disease that threatens to the health of global elderly population. Acetylcholinesterase (AChE) inhibitors are an effective therapeutic agent for AD, and screening of these substances is important for AD treatment. In this work, a Pd-Pt MXene nanoenzyme was successfully synthesized by using the in-situ reduction technique. A colorimetric method for sensitive AChE inhibitor detection was designed based on enzymatic cascade reaction between Pd-Pt MXene and AChE. Briefly, The Pd-Pt MXene material exhibited excellent peroxidase (POD)-like activity due to its bimetallic composition, effectively catalyzing the oxidation of colorless 3,3,5,5-tetramethylbenzidine (TMB) to generate blue oxidized TMB (oxTMB). Under the presence of AChE and acetylthiocholine chloride (ATCh), the POD-like activity of Pd-Pt MXene was significantly inhibited. The activity of this nanoenzyme could be restored after the addition of AChE inhibitors. Using donepezil as an example, colorimetric detection was conducted within a linear range of 0.1 nmol/L to 10 nmol/L and the lowest detection boundary was only 0.35 nmol/L (S/N = 3). Finally, a paper-based platform was designed and constructed, and it has been successfully employed for AChE inhibitor detection in real samples with the aid of a smartphone. In all, this work paves a new way for designing nanoenzyme-based devices towards medicine determination or screening like AChE inhibitor.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zhang, L., Li, A., Shen, M., Zhang, Z., Wufuer, R., & Wang, D. (2025). Palladium-platinum bimetallic modified MXene nanozyme for highly sensitive detection of active substances with acetylcholinesterase inhibitory effect. Talanta. https://doi.org/10.1016/j.talanta.2024.127020

Vancouver

Zhang L, Li A, Shen M, Zhang Z, Wufuer R, Wang D. Palladium-platinum bimetallic modified MXene nanozyme for highly sensitive detection of active substances with acetylcholinesterase inhibitory effect. Talanta. 2025. doi:10.1016/j.talanta.2024.127020. PMID: 39406077.

BibTeX

@article{zhang2025-39406077,
  author  = {Zhang, L. and Li, A. and Shen, M. and Zhang, Z. and Wufuer, R. and Wang, D.},
  title   = {{Palladium-platinum bimetallic modified MXene nanozyme for highly sensitive detection of active substances with acetylcholinesterase inhibitory effect}},
  journal = {Talanta},
  year    = {2025},
  doi     = {10.1016/j.talanta.2024.127020},
  pmid    = {39406077},
  url     = {https://doi.org/10.1016/j.talanta.2024.127020}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read 0 of 2. 24 of the 58 points it could be judged on, which is 41 of 100. Total 41 of 100.24 of the 58 points we could judge = 41 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 24 of the 58 points we could judge it on, which is 41 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Talanta)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39406077)
Free to read 0 / 2 Behind a paywall — scores zero
Points 24 / 58 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 24 of the 58 points we could judge it on is 41 out of 100.
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Related studies in Cognitive tests and assessment

Also tagged “modified”

4 studies in the library carry the topic tag “modified”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.

Similar studies

More on Cognitive tests and assessment

See all studies in Cognitive tests and assessment →